About Ubenimex

»»About Ubenimex
About Ubenimex2017-02-07T22:03:47+00:00

Ubenimex is a well-characterized, oral, small-molecule, dual-inhibitor of aminopeptidase and leukotriene A4 hydrolase (LTA4H), the enzyme responsible for catalyzing the committed step in the formation of the proinflammatory mediator, LTB4. Ubenimex is approved in Japan as an adjunct to chemotherapy agents to extend survival and to maintain remission after treatment for acute non-lymphocytic leukemia in adults. Ubenimex has been used for over 25 years in Japan and remains commercially available through Nippon Kayaku. Ubenimex is not approved for any indication in the U.S. or Europe.


For more information, please visit www.clinicaltrials.gov: NCT02700529.

Nippon Kayaku markets ubenimex under the trade name Bestatin™.


Pulmonary Arterial Hypertension